Search Results for: disease

By Kuldip K. Ambastha The stock of Regeneron Pharmaceuticals, Inc. (REGN), a biotechnology company with a portfolio of medicines for individuals with serious diseases, increased in price by +18.8% per share on the trading day of Thursday, September 8, 2022. Eylea (aka: aflibercept), an anti-blindness eye medication, was the cause of this price run-up, because …

Continue reading “What Caught Our Attention in the Investment World? – Week of September 6-9, 2022”

By Kuldip K. Ambastha Longeveron Inc. (LGVN), a biotechnology company focused on clinical stage therapies, had its stock price rise by +105.4% per share on Thursday, March 31, 2022. On this trading day, a great piece of news led to a great return. Lomecel-B has shown positive results from its Phase 1 trial testing on …

Continue reading “What Caught Our Attention in the Investment World? – Week of March 28-April 1, 2022”

By Kuldip K. Ambastha On Friday, September 3, 2021, the stock of Forte Biosciences, Inc. (FBRX) stood out for its substantial trading day loss of -82.3%. Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on potential treatments for inflammatory skin diseases. The company released results of a Phase 2 clinical trial of FB-401, related …

Continue reading “What Caught Our Attention in the Investment World? – Week of August 30-September 3, 2021”

By Kuldip K. Ambastha Biogen Inc. (BIIB), a biotech company, had a memorable Monday of this past trading week. On Monday, June 7, 2021, Biogen had a +38.3% gain for the day on its stock. Biogen’s Alzheimer’s disease treatment was approved by the U.S. Food and Drug Administration (FDA) as part of an accelerated approval …

Continue reading “What Caught Our Attention in the Investment World? – Week of June 7-11, 2021”

By Kuldip K. Ambastha and Anil K. Ambastha On Tuesday, February 25, 2020, the stock of Moderna, Inc. (MRNA) rose by 27.8% for the day. As the coronavirus (COVID-19) has spread around the world and led to a sell-off in the capital markets, Moderna, Inc. announced that its coronavirus vaccine candidate is scheduled to be …

Continue reading “What Caught Our Attention in the Investment World? – Week of February 24-28, 2020”

By Kuldip K. Ambastha and Anil K. Ambastha On Monday, December 9, 2019, big news emerged in the mergers & acquisitions field in terms of Merck & Co., Inc. (MRK) buying ArQule, Inc. (ARQL) and Sanofi SA (SNY) buying Synthorx Inc. (THOR). Both Merck and Sanofi bought the smaller companies to enhance their capabilities in …

Continue reading “What Caught Our Attention in the Investment World? – Week of December 9-13, 2019”

By Kuldip K. Ambastha and Anil K. Ambastha Acadia Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company which has Nuplazid (aka: pimavanserin) in its product pipeline. Nuplazid has been used by individuals suffering from Parkinson’s disease-linked psychosis. Acadia has now analyzed Nuplazid in relation to individuals suffering from dementia-related psychosis. Currently, no approved drugs exist in …

Continue reading “What Caught Our Attention in the Investment World? – Week of September 9-13, 2019”